Congenital JAK2V617F polycythemia vera: where does the genotype-phenotype diversity end?

1. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362-371. 2. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743. 3. Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by antiCD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:10451052. 4. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-174. 5. Beers S, Chan H, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody outperforms Type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. Prepublished on July 10, 2008, as DOI 10.1182/blood-2008-04-149161. 6. Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab )(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15-24. 7. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908.